

Patient Enrollment Form for VIMIZIM® (elosulfase alfa)

Fax completed form with prescriber's signature to 1.888.863.3361 To learn more about BioMarin RareConnectionsTM call 1.866.906.6100, hours M–F, 8 AM–8 PM (ET)



All required fields are purple and bolded

	1.1									
PATIENT	First Name		Mide	Middle Initial Last Name				Suffix		
	Date of Birth (mm/dd/yyyy) Gender ☐ Male ☐ Female ☐ Other									
	Address							Floor/Suite/ Unit		
	City							ZIP Code		
	Primary Phone									
	Preferred Method of Contact Preferred Language: ☐ English ☐									
	☐ Primary Phone ☐ Mobile Phone ☐ Email ☐ Other language (please specify)									
	Authorized Representative Name (if applicable)						Relation	ship to Patient		
	Phone Email						1			
PRESCRIBER	First Name	· · · · · · · · · · · · · · · · · · ·								
	Specialty				NPI Number					
	State License Number Medi			edicaid Number			Tax ID			
	Name of Institution/Practice									
	Address							Floor/Suite/Unit		
	City							ZIP Code		
	Phone	Fax			Email					
	Preferred Method of Contact Phone Email									
	Primary Contact Name (if different from prescriber)									
	Phone	Fax			Email					
	Provide copies of all medical and prescription cards — front and back									
	☐ Patient has no insurance									
INSURANCE	Primary Medical Insurance Name				Inst			surance Phone		
	Subscriber Name Relationship to Patient									
	Marrhagil									
	Member ID Group			IP P			Plan Code			
							Insurand	nsurance Phone		
	Subscriber Name									
	Member ID	RxBIN			RxPCN		RxGROUP			

Patient's F	ull Name					0	Date of Birtl	h (mm/dd/yyyy)		
	Infusion Site Name									
INFUSION SITE	Address							Floor/Suite/Unit		
	City					State	ZIP Code			
	Infusion Site NPI	Infus	Infusion Site Tax ID			Infusion Site Contact (if available)				
	Phone		Fax Email							
	If diagnosis is confirmed please fill out the information below:									
CLINICAL/DIAGNOSIS	☐ ICD-10 Code (Morquio A, Mucopolysaccharidosis, E76.210)						Date of diagnosis (mm/dd/yyyy)			
	Lab performing diagnosis									
AL/D	Method of diagnosis									
LINIC	Patient allergies □ NKDA □ Yes (please list)									
S	Concurrent medications									
	For Use by In-Network Specialty Pharmacy Only—Not for Home Infusion									
Z	Product name: VIMIZIM® (elosulfase alfa), concentrate for infusion			NDC Number: 68135-100-01						
PRESCRIPTION	Current weight (kg) Date	e weight meas	ured (mm/dd/yyyy)	yy) Dose (mg per week)						
SCR	Dispense:	Direction for use:								
REG	Number of days' supply/Rx: 🗆 30 days 🗀 90 days Refills: One (1) year Infuse mg every week in mL normal saline over hours									
<u>.</u>	Preferred Procurement Method ☐ Buy and Bill ☐ Specialty Pharmacy									
PRESCRIBER DECLARATION	Prescriber Declaration: I verify that the patient and prescriber information contained in this enrollment form is complete and accurate to the best of my knowledge and that I have prescribed VIMIZIM® (elosulfase alfa) based on my professional judgment of medical necessity. I authorize BioMarin or its affiliated companies or subcontractors to forward this prescription electronically, by facsimile, or by mail to a dispensing pharmacy chosen by the above-mentioned patient. I also authorize BioMarin to perform any steps necessary to obtain reimbursement for VIMIZIM, including but not limited to insurance verification and									
	case management. I understand that BioMarin may need additional information, and I agree to provide it as needed for purposes of reimbursement. Prescriber's Signature. Please make a selection									
	Prescriber's Signature/Dispense as Written (no stamps or initials)	Date	Prescriber's Signature/Su (no stamps or initials)	bstitution Pe	rmitted		Date			
	No stamps or initials: If you are a New York prescriber, please use an original New York State prescription form.									

PATIENT CONSENT FORM

To learn more about BioMarin RareConnections™ call 1.866.906.6100, hours M–F, 8 AM–8 PM (ET)



References to "you," "Jour," "I," "me," "my," etc. in this form are to the patient, even if an authorized representative is signing this form on the patient's behalf.

FOR BIOMARIN TO ASSIST YOU WITH ITS MEDICINES AND RELATED CARE, YOU WILL NEED TO PROVIDE CONSENT TO BOTH YOUR HEALTHCARE PROVIDER AND BIOMARIN:

- · Your healthcare provider needs your written consent to release your protected health information (PHI) to BioMarin
- BioMarin needs your written consent to share your information with service providers such as laboratories and pharmacies to assist you with accessing services that support your treatment
- BioMarin needs your consent to contact you with marketing and other communications about BioMarin's products, services, programs, and
 other topics of interest for marketing, educational, or other purposes; to assist you in getting help through additional services that support your
 treatment plan; and to allow you to provide feedback to BioMarin through market research
- As described below, your consent is voluntary and is not required for treatment, medications, or other care. Your consent is required for BioMarin to provide the product support services described here
- BioMarin and its agents and representatives do not work under the direction of your healthcare provider or give medical advice; they are trained to direct patients to their healthcare provider for treatment-related advice

SECTION A: CONSENT TO SHARE HEALTH INFORMATION FOR PATIENT SUPPORT SERVICES

By signing this Patient Consent Form (PCF), I hereby authorize my healthcare providers, health insurance carriers, laboratory providers, and pharmacy providers (collectively, Healthcare Entities) to use and disclose my individual health and identifying information, including but not limited to health insurance information, medical diagnosis and condition (including but not limited to laboratory test results such as diagnostic results as well as test results related to diagnosis or supportive testing), prescription information, and name, date of birth, sex, address, and telephone number to BioMarin and its agents and representatives, including but not limited to third parties authorized by BioMarin, for them to use for the purposes listed below. I further authorize BioMarin to use my individual health and identifying information to administer the patient support program through BioMarin RareConnectionsTM. Authorized purposes:

- to assist me with accessing services that support my treatment;
- to contact my healthcare provider and collect, enter, and maintain my health information in a database;
- to contact my insurers as needed to verify my insurance coverage, review reimbursement requirements, verify other financial assistance for which I might be eligible, assist with the processing of claims, or otherwise assist in obtaining coverage or financial assistance for my treatment, including but not limited to in relation to post-administration monitoring (n/a for Veteran's Administration (VA) patients);
- to determine eligibility for program offerings, including but not limited to financial assistance services (financial assistance n/a for VA patients);
- to determine eligibility for a BioMarin Co-Pay Assistance program, valid ONLY for qualifying patients residing in the 50 U.S. states or in Puerto Rico, where not prohibited by law, with commercial insurance, who are not a government beneficiary and/or participant in a federal or state-funded health insurance program, and who have a valid prescription for an FDA-approved indication for the qualifying BioMarin therapy; the BioMarin Co-Pay Assistance program pays for eligible out-of-pocket costs, where applicable, associated with a qualifying BioMarin therapy up to a maximum amount per calendar year;
- to contact me to follow up on any BioMarin RareConnections enrollment requirements, discuss and provide information and education on my treatment and any follow-up requirements, discuss the effectiveness of patient support services, and provide patient support services, education, and adherence reminders such as to take my BioMarin medication; and
- if I sign under Section 3, I further authorize BioMarin to use my individual and health and identifying information for the purposes described in Section B.

Once my health information has been disclosed to BioMarin, I understand that certain federal privacy laws may no longer protect the information. However, BioMarin intends to protect my health information by using and disclosing it only for purposes described in this PCF or as permitted by law or regulations. California residents, to learn more about the information BioMarin may collect about you, how we use that information, and your rights under the California Consumer Privacy Act (CCPA), please review our CCPA Privacy Policy, available at biomarin.com/data-privacy-center. I understand that pharmacy providers, or others working on their behalf, may receive remuneration from BioMarin in exchange for patient therapy support services and data provided.

I understand that any product(s) provided under BioMarin's temporary Bridge Support program are for my/my child's personal use and will not be sold, traded, bartered, or transferred. Completing this form does not guarantee that I/my child will qualify for BioMarin's temporary Bridge Support program. In the event I become eligible for BioMarin's temporary Bridge Support program, I understand and agree as follows:

- BioMarin Bridge is not health insurance and is available for eligible patients only.
- Offer is available only to patients who have been diagnosed with an FDA-approved indication for a BioMarin therapy.
- No claim for reimbursement for product dispensed pursuant to this program may be submitted to my prescription insurance provider or any other third-party payer, including Medicare.
- To be eligible for Bridge, I/my child must be actively pursuing coverage through my insurance or awaiting a prior authorization/appeal decision.
- BioMarin Bridge does not require, nor will be made contingent on, purchase requirements of any kind.
- BioMarin reserves the right to amend, rescind, or discontinue this program at any time without notification.
- BioMarin Bridge can be dispensed only by the exclusive pharmacy and only after benefits investigation has been completed and a delay occurs in the prior authorization or appeals process or a new-to-market block by the payer has been confirmed.

- BioMarin Bridge is available only to patients in the U.S. and Puerto Rico.
- Prescription must be provided by a healthcare provider licensed in the U.S. or Puerto Rico.
- Additional eligibility criteria may apply. Contact BioMarin RareConnections for details.

This PCF expires in ten (10) years, or such shorter amount of time required by applicable state law, after the date I sign it as indicated by the date next to my signature, unless otherwise canceled earlier as set forth below. I understand I have a right to receive a copy of this PCF.

I understand that I may refuse to sign this PCF. I further understand that my treatment (including with a BioMarin product), payment for treatment, insurance enrollment, or eligibility for insurance benefits are not conditioned upon my agreement to sign this PCF, but if I do not sign it, or if I later cancel it, I will not be able to receive BioMarin's patient support services.

I understand that I may cancel this PCF at any time by mailing a letter to BioMarin at BioMarin RareConnections at 680 Century Point, Lake Mary, FL 32746 or emailing support@biomarin-rareconnections.com. Canceling this PCF will end my consent for my Healthcare Entities to further use and disclose my health information to BioMarin after they are notified of my cancellation but will not affect previous disclosures by them pursuant to this PCF. Canceling this PCF will not affect my ability to receive treatment, payment for treatment, or my eligibility for health insurance.

SECTION B: CONSENT FOR MARKETING/OTHER COMMUNICATIONS

By signing this Patient Consent Form (PCF), I hereby authorize my Healthcare Entities to use and disclose my individual health and identifying information to BioMarin for marketing purposes or to otherwise provide me with information about BioMarin products, services, research, clinical trials, and programs or other topics of interest, and to conduct market research or otherwise ask me about my experience with or thoughts about such topics. I understand and agree that BioMarin and companies working with BioMarin may use my individual health and identifying information to contact me by mail, email, fax, telephone call, or text message for these purposes. I understand and agree that any information that I provide may be used by BioMarin to help develop new products, services, and programs. I further understand that BioMarin will not sell or transfer my personal data to any unrelated third party for marketing purposes without my express permission.

1 To authorize your consent, please complete all fields below.

						Gender	☐ Male	☐ Fema	le D Other
Patient's First Name	Middle Initial	Patient's Last Name		Suffix	Date of Birth				
Patient's/Authorized Repr	esentative's Name (if	applicable)		Relation	ship to Patient				
Patient's/Authorized Repr	esentative's Address		Floor/Suite	/Unit	City			State	ZIP Code
Preferred Method of Cont	act (please specify)	☐ Primary Phone							
☐ Mobile Phone (leave b	olank if mobile is prim	ary phone)			_				
Preferred Language	English	sh 🔲 Other Language (pl	lease specify)						
I have read and unde		w. in this PCF, the Conserequired in order to rec				atient Suppo	rt Service	s, and ag	ree to the terms
Patient's/Authorized Repr	esentative's Signatur	e				Date			
Print Authorized Represen	ntative's Name (if app	olicable)				Relationship	to Patient		
	and sign beloerstand Section B	w. in this PCF, the Conse	ent for Marketi	ng/Othe	er Communication	ons, and agr	ee to the	terms sta	ted therein.
Patient's/Authorized Repr	esentative's Signatur	е				Date			
Print Authorized Represei	ntative's Name (if app	olicable)				Relationship	to Patient		

Print and fax your completed form (both pages) to 1.888.863.3361.

Note for healthcare providers: once your patient has completed this form, provide a copy to them and place the original in the patient's medical record.



©2023 BioMarin Pharmaceutical Inc. All rights reserved. US-VIM-00086 0323

